---
search:
  boost: 2 
---

# Atypical Antipsychotics

This is a subcategory of Central Nervous System (CNS) Agents.

## Formulary

### Preferred

| Preferred                       | Generic Name | Quantity | Time (Days) |
| :------------------------------ | :----------- | :------: | :---------: |
| Abilify Maintena <sup>QL</sup>  |              |          |             |
| Aripiprazole <sup>QL</sup>      |              |          |             |
| Aristada <sup>QL</sup>          |              |          |             |
| Aristada Initio                 |              |          |             |
| Clozapine                       |              |          |             |
| Fanapt <sup>ST</sup>            |              |          |             |
| Geodon <sup>QL</sup>            |              |          |             |
| Invega Tab <sup>BvG</sup>       |              |          |             |
| Invega Hafyera ER <sup>PA</sup> |              |          |             |
| Invega Sustenna <sup>QL</sup>   |              |          |             |
| Invega Trinza <sup>QL</sup>     |              |          |             |
| Latuda <sup>ST QL</sup>         |              |          |             |
| Olanzapine <sup>QL</sup>        |              |          |             |
| Perseris                        |              |          |             |
| Quetiapine IR <sup>QL</sup>     |              |          |             |
| Quetiapine ER <sup>QL</sup>     |              |          |             |
| Risperdal Consta <sup>QL</sup>  |              |          |             |
| Risperidone <sup>QL</sup>       |              |          |             |
| Saphris <sup>BvG ST</sup>       |              |          |             |
| Ziprasidone <sup>QL</sup>       |              |          |             |

### Non-Preferred

| Non-Preferred                  | Generic Name | Quantity | Time (Days) |
| :----------------------------- | :----------- | :------: | :---------: |
| Abilify Mycite                 |              |          |             |
| Aripiprazole Sol               |              |          |             |
| Asenapine                      |              |          |             |
| Caplyta                        |              |          |             |
| Clozapine ODT Rapdis           |              |          |             |
| Fluoxetine/Olanzapine          |              |          |             |
| Lybalvi                        |              |          |             |
| Nuplazid                       |              |          |             |
| Olanzapine ODT                 |              |          |             |
| Paliperidone                   |              |          |             |
| Rexulti                        |              |          |             |
| Secuado                        |              |          |             |
| Versacloz                      |              |          |             |
| Vraylar                        |              |          |             |
| Zyprexa Relprevv <sup>QL</sup> |              |          |             |

## Length of Authorizations

365 Days

## Grandfathering

Patients who have a claim for a non-preferred drug, or drug requiring step therapy, in the previous 120 days will be automatically approved to continue the drug. Patients who have taken the drug in the previously, but do not have claims history (e.g. new to Medicaid), will need to submit a prior authorization in order to continue coverage.

### Psychiatrist Exemption

Providers (as identified below) are exempt from prior authorization of any non-preferred second-generation antipsychotic, or step therapy of any preferred brand, in the standard tablet/capsule dosage forms. Other dosage forms may still require prior authorization. The exemption will be processed by the claims system when the pharmacy has submitted the prescriber on the claim using the individual national provider identifier (NPI) for the provider.

**FFS**: Physicians who are registered with Ohio Medicaid as having a specialty in psychiatry

**MCOs**: Physicians with a specialty in psychiatry, nurse practitioners certified in psychiatric mental health, or clinical nurse specialists certified in psychiatric mental health, who are credentialed via the Medicaid managed care plan

## All Authorizations

Must be prescribed in accordance with FDA approved labeling

## Paliperidone Palmitate (Invega Hafyera)

Paliperidone Palmitate (Invega Hafyera) Criteria

- Must have had 4 months of treatment with Invega Sustenna or 3 months with Invega Trinza

### Step Therapy

Step Therapy Approval

- Must have had an inadequate clinical response of at least **30 days** with at least **one preferred** drug

## Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least **30 days** with at least **two preferred** drugs
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

## Additional Criteria

### Aripiprazole (Abilify Mycite)

Additional Aripiprazole (Abilify Mycite) Criteria

- Must be prescribed by or in consultation with a psychiatrist following an aripiprazole serum blood level draw indicating need for further investigation of adherence

### Olanzapine / Samidorphan (Lybalvi)

Additonal Olanzapine / Samidorphan (Lybalvi) Criteria

-  Must provide documentation that patient is not using opioids or undergoing acute opioid withdrawal

### Pimavanserin (Nuplazid)

Additional Pimavanserin (Nuplazid) Criteria

- For Parkinson-related Hallucinations & Delusions ALL of the following must be met:
  - Psychotic symptoms are severe and frequent enough to warrant treatment with an antipsychotic AND are not related to dementia or delirium
  - The patient’s other Parkinson’s Disease drugs have been reduced or adjusted and psychotic symptoms persist OR patient is unable to tolerate adjustment of these other drugs
  - Must have been inadequate clinical response or contraindication to at least 30 days of either quetiapine or clozapine
- An exemption to the criteria will be authorized for prescribers with a neurology specialty to a patient with a history of the related condition

### Fluoxetine / Olanzapine (Symbyax)

Additional Fluoxetine / Olanzapine (Symbyax) Criteria

- Must provide documentation for patient’s inability to use the individual drugs

## Additional Information

- Long-acting injectable antipsychotics may be billed by the pharmacy if they are not dispensed directly to the patient. If not administered by the pharmacist, the drug must be released only to the administering provider or administering provider’s staff, following all regulations for a Prescription Pick-Up Station as described by the Ohio Board of Pharmacy

## Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL%20_Criteria_APPROVED.pdf#page=35)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL_APPROVED_12.13.22.pdf#page=16)

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf)
